|Day Low/High||72.04 / 73.16|
|52 Wk Low/High||65.47 / 99.14|
The Trump administration's creep towards scrapping certain tax regulations could revive inversion deals that have allowed U.S. companies to avoid billions of dollars in taxes.
The top executives at these seven companies all left after pressure from activist investors in 2017.
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
Valeant is selling its Australian unit iNova to raise $930 million to pay down debt.
Stocks significantly pared losses by the end of the session, though still ended slightly lower.
The quarter's success, Canaccord Genuity analyst Dewey Steadman argued, means Perrigo has removed an overhang.
Core CPI has slowed on a year-over-year basis now for three consecutive months.
The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.
David Einhorn is going all-in on General Motors.
New Directors Nominated by Starboard in Accordance With Previously Announced Agreement
Doug Kass shares his thoughts on Facebook, Allergan and Apple.
Stocks hold mostly lower on Wednesday after the Federal Reserve's policy-making group decides to leave its federal funds rate unchanged.
The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.
Goldberg Law PC announces that it is investigating Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) concerning possible violations of federal securities laws.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Perrigo Co.